U.S. markets open in 1 hour 15 minutes
  • S&P Futures

    3,430.25
    -2.25 (-0.07%)
     
  • Dow Futures

    28,122.00
    -12.00 (-0.04%)
     
  • Nasdaq Futures

    11,691.50
    +0.25 (+0.00%)
     
  • Russell 2000 Futures

    1,609.50
    +6.40 (+0.40%)
     
  • Crude Oil

    40.36
    +0.33 (+0.82%)
     
  • Gold

    1,916.40
    -13.10 (-0.68%)
     
  • Silver

    24.93
    -0.31 (-1.23%)
     
  • EUR/USD

    1.1825
    -0.0042 (-0.35%)
     
  • 10-Yr Bond

    0.8160
    0.0000 (0.00%)
     
  • Vix

    29.17
    -0.18 (-0.61%)
     
  • GBP/USD

    1.3096
    -0.0048 (-0.36%)
     
  • USD/JPY

    104.6600
    +0.1000 (+0.10%)
     
  • BTC-USD

    12,912.32
    +1,855.31 (+16.78%)
     
  • CMC Crypto 200

    260.37
    +15.48 (+6.32%)
     
  • FTSE 100

    5,787.07
    +10.57 (+0.18%)
     
  • Nikkei 225

    23,474.27
    -165.19 (-0.70%)
     

IGM Biosciences to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

IGM Biosciences
·1 min read

MOUNTAIN VIEW, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11 at 1:45 p.m. ET.

A live webcast of the presentation will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

Contact:

Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com